The role of Asprosin in the diagnosis of diabetic and non-diabetic patients with sepsis

Sepsis is among the major causes of mortality in the world due to its delayed diagnosis and inadequate treatment. Due to the high morbidity and mortality rates, a widely accepted biomarker is required for its diagnosis. Present study aimed to evaluate the serum asprosin levels in septic patients and determine its potential use as a biomarker for its diagnosis. A prospective cohort study was performed with total 81 participants. These were divided in two groups, i.e., 54 septic patients and 27 healthy volunteers (control group). Among 54 septic participants, half (27) were diabetic, and half (27) were nondiabetic. Blood samples (3 mL) were collected from the control group and the patients who were diagnosed with sepsis and transferred to serum seperator tube. Samples were fractioned and stored at −80 ◦C for further evaluation. These samples were used for the measurement of serum asprosin levels. Demographic characteristics and laboratory data of the patients were recorded in the study form prepared previously. The serum asprosin levels in the control group were 4.1 ± 1.4 ng/mL, 32.8 ± 7 ng/mL in the non-diabetic septic patients and 90.7 ± 5.5 ng/mL in diabetic septic patients. The asprosin level in the non-diabetic group were higher as compared to the control group (p: 0.012), and it was statistically significantly higher in the diabetic group compared to the non-diabetic septic and control groups (both: p < 0.001). Serum asprosin levels were significantly higher in patients with sepsis specially having diabetes. Serum asprosin levels may be beneficial for the diagnosis of sepsis especially in diabetic patients along with the other laboratory parameters white blood cells (WBC), C-reactive protein (CRP), sequential organ failure assessment score (SOFA score) and fewer.

Asprosin; Diabetes mellitus; Diagnosis; Sepsis

[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315: 801–810.

[2] Vincent J. Current sepsis therapeutics. EBioMedicine. 2022; 86: 104318.

[3] Dellinger RP, Rhodes A, Evans L, Alhazzani W, Beale R, Jaeschke R, et al. Surviving sepsis campaign. Critical Care Medicine. 2023; 51: 431–444.

[4] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. American Journal of Respiratory and Critical Care Medicine. 2016; 193: 259–272.

[5] Komorowski M, Green A, Tatham KC, Seymour C, Antcliffe D. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine. 2022; 86: 104394.

[6] Feng S, Zhang J. Clinical and microbiological characteristics of type 2 diabetes mellitus accompanied with sepsis. Clinical Laboratory. 2023; 69: 840.

[7] Zonneveld R, Molema G, Plötz FB. Analyzing neutrophil morphology, mechanics, and motility in sepsis. Critical Care Medicine. 2016; 44: 218–228.

[8] Costantini E, Carlin M, Porta M, Brizzi MF. Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. Acta Diabetologica. 2021; 58: 1139–1151.

[9] Lu Z, Tao G, Sun X, Zhang Y, Jiang M, Liu Y, et al. Association of blood glucose level and glycemic variability with mortality in sepsis patients during ICU hospitalization. Frontiers in Public Health. 2022; 10: 857368.

[10] Donma MM, Donma O. Asprosin: Possible target in connection with ghrelin and cytokine network expression in the post-burn treatment. Medical Hypotheses. 2018; 118: 163–168.

[11] Handa K, Abe S, Suresh VV, Fujieda Y, Ishikawa M, Orimoto A, et al. Fibrillin-1 insufficiency alters periodontal wound healing failure in a mouse model of Marfan syndrome. Archives of Oral Biology. 2018; 90: 53–60.

[12] Sipahioglu H, Sen O, Koyuncu S, Kuzugüden S. Serum asprosin level as a new biomarker in differentiating familial mediterranean fever attacks. Cureus. 2023; 15: e35342.

[13] Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation. 2018; 2018: 1–7.

[14] Diao H, Li X, Xu Y, Xing X, Pang S. Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus. Journal of Diabetes and its Complications. 2023; 37: 108614.

[15] Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Military Medical Research. 2022; 9: 56.

[16] Gauer R, Forbes D, Boyer N. Sepsis: diagnosis and management. American Family Physician. 2020; 101: 409–418.

[17] Ma H, Zhang G, Mou C, Fu X, Chen Y. Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Frontiers in Pharmacology. 2018; 9: 156.

[18] Stocker M, van Herk W, el Helou S, Dutta S, Schuerman FABA, van den Tooren-de Groot RK, et al. C-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study. Clinical Infectious Diseases. 2021; 73: e383–e390.

[19] Huang Y, Chen C, Shao S, Li C, Hsiao C, Niu K, et al. Comparison of the diagnostic accuracies of monocyte distribution width, procalcitonin, and C-reactive protein for sepsis: a systematic review and meta-analysis. Critical Care Medicine. 2023; 51: e106–e114.

[20] Acara AC, Bolatkale M, Kızıloğlu İ, İbişoğlu E, Can Ç. A novel biochemical marker for predicting the severity of ACS with unstable angına pectoris: asprosin. American Journal of Emergency Medicine. 2018; 36: 1504–1505.

[21] Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Frontiers in Endocrinology. 2020; 11: 64.

[22] Lee YS, Olefsky J. Chronic tissue inflammation and metabolic disease. Genes & Development. 2021; 35: 307–328.

[23] Zeng G, Chen D, Zhou R, Zhao X, Ye C, Tao H, et al. Combination of C-reactive protein, procalcitonin, IL-6, IL-8, and IL-10 for early diagnosis of hyperinflammatory state and organ dysfunction in pediatric sepsis. Journal of Clinical Laboratory Analysis. 2022; 36: e24505.